Scarica l'app Stockscreener
95.35
3.36%
3.10
Dopo l'orario di chiusura:
95.80
0.45
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year HighWhat's Next? - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL - MarketBeat
683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 93.53 USD By Investing.com - Investing.com Australia
Citizens maintains Protagonist Therapeutics stock rating, citing rusfertide efficacy By Investing.com - Investing.com Canada
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
VIX Spike: How Protagonist Therapeutics Inc stock benefits from strong dollar2025 Winners & Losers & Fast Entry Momentum Trade Alerts - moha.gov.vn
How (PTGX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
High Growth Tech Stocks In The US Market With Potential - Yahoo Finance
Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Daily Comet
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - theglobeandmail.com
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Press & Sun-Bulletin
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Livingston Daily
Is Rusfertide’s Phase 3 VERIFY Durability Data Altering The Investment Case For Protagonist Therapeutics (PTGX)? - Sahm
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Asbury Park Press
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - STT Info
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Central New Jersey News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Insider Monkey
Is Protagonist Therapeutics (PTGX) Overvalued After Its Recent Biotech Rally? A Fresh Look at the Valuation - Sahm
What dividend safety score for Protagonist Therapeutics Inc. stock2025 Earnings Surprises & Trade Opportunity Analysis Reports - Newser
How currency fluctuations impact Protagonist Therapeutics Inc. stock2025 Year in Review & Scalable Portfolio Growth Ideas - Newser
How Protagonist Therapeutics Inc. stock compares to growth peers2025 Earnings Surprises & High Accuracy Investment Entry Signals - Newser
Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Skandinaviska Enskilda Banken AB publ Lowers Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Trading Systems Reacting to (PTGX) Volatility - news.stocktradersdaily.com
Ensign Peak Advisors Inc Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by American Century Companies Inc. - MarketBeat
Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Creative Planning - MarketBeat
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Oak Ridger
Why Protagonist Therapeutics Inc. stock remains undervaluedDividend Hike & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - Newswire.com
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Protagonist Therapeutics Reaches Analyst Target Price - Nasdaq
Jefferies Financial Group Inc. Buys 192,126 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
120,159 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Segall Bryant & Hamill LLC - MarketBeat
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan
Geode Capital Management LLC Buys 20,671 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Intech Investment Management LLC Acquires 2,971 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):